The automated cell culture market is advancing as biopharmaceutical developers and research laboratories seek greater efficiency, consistency, and scalability. Valued at USD 20.99 billion in the base year 2025, the automated cell culture market is projected to reach USD 23.69 billion in 2026 and USD 63.15 billion by 2034, growing at a CAGR of 13.02% during the forecast period 2026–2034. Key players include Thermo Fisher Scientific, Sartorius AG, Danaher Corporation, Merck KGaA, Lonza Group Ltd., and Corning Incorporated.

What Automation Delivers in Cell Culture Workflows

Cell culture automation uses robots, artificial intelligence, and digital surveillance to manage cellular growth, development, and study with minimal human intervention. Demand for automated cell culture systems is rising with the shift toward precision medicine and cell therapy development, and these platforms also support tissue engineering and advanced therapeutic development across research and clinical pipelines.

Biopharmaceutical firms are adopting biopharmaceutical automation solutions to boost productivity while lowering errors in cell handling protocols. Advances in robotics, software, and real-time monitoring continue to improve system performance, and quality assurance, process standardization, and cost optimization are expected to support growth.

Specialized equipment improves efficiency and consistency in cell manipulation processes, and the technology is popular in biopharmaceutical and research settings. The challenges of manufacturing biological drugs and conducting clinical tests have played a significant role in creating demand for automation, and expansion of regenerative medicine research has created strong demand for scalable, reproducible culture processes. AI improves process optimization, enhances monitoring capabilities, and increases efficiency in cell culture workflows.

Browse Full Insights:

https://www.polarismarketresearch.com/industry-analysis/automated-cell-culture-market

Growth Drivers in the Automated Cell Culture Market

Rising biologics demand strengthens the case for automation. The report cites projections that global biologics consumption will reach USD 569.7 billion by 2027, growing at 9.2% annually. Robotic cell culture systems help meet this need by minimizing human intervention and providing tighter process control.

Reproducibility is a second driver. Human involvement introduces inconsistencies that affect experimental outcomes and product quality, whereas automated incubation of cells and intelligent cell cultures deliver greater consistency and control over experimental parameters.

The requirement for reproducibility ensures the need to adopt automation and AI-powered cell manipulation tools. Growth is therefore driven by increasing biologics production, rising demand for automation in laboratories, and expanding regenerative medicine research. Automation addresses higher biologics volumes, the demand for reproducible results, and the need to limit manual handling errors, while AI-based integration offers promising additional growth potential.

Segment Insights: Systems, Consumables, and End Users

Among products, automated systems dominated in 2025 with nearly 29.20% share, driven by strong adoption in laboratory studies and manufacturing, with benefits of fewer errors and high-throughput processing. Consumables, including media, reagents, and cell culture containers, are projected to grow at a CAGR of around 11.10% on recurring demand.

Drug discovery accounted for the largest application share in 2025 as drug discovery automation speeds screening and shortens development timelines. In April 2026, OpenAI revealed GPT-Rosalind, an AI model designed to accelerate early-stage drug discovery. By end user, biopharma led with approximately 43.50% share, while CROs are expected to register the highest growth as research and development outsourcing rises.

North America was the largest market in 2025. The report segments products into automated systems, consumables, and software, applications such as drug discovery and biopharmaceutical production, and end users including biopharmaceutical companies, CROs and CDMOs, and academic and research institutes. Consumables generate constant earnings because they are essential to ongoing operations. Biopharma users prefer automation for efficiency and quality control, and CROs use it to handle intricate processes efficiently.

Challenges and AI-Driven Opportunity

High capital cost remains the main barrier because robots, software, and facility changes are required, making adoption difficult for small laboratories. Integration with existing lab settings, technical or software issues that may cause contamination, and a shortage of trained personnel add risk.

AI offers a counterweight. In January 2026, Automated Cell Culture as formed a strategic alliance with Cellvoyant to develop an AI-based closed cell culture process workflow system using predictive analytics and lab automation tools, improving monitoring, efficiency, and accuracy.

More Trending Latest Reports By Polaris Market Research:

Gynecological Examination Chairs Market

Fluoropolymers Market

Safari Tourism Market

Enterprise Content Management Market

Automotive Ceramics Market

Mass Flow Controller Market

Hemophilia A Treatment Market

AI Trust, Risk and Security Management Market